Desmoid tumour: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Advanced, first line	1
Second line	1
Other settings	1

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Newly diagnosed, asymptomatic or minimally symptomatic	Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.	Active surveillanceMRI	NCCN · Category 2A (observation)	80

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Progressive or symptomatic disease	Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.	NirogacestatSorafenibDeFiMethotrexate	NCCN · Category 1 (nirogacestat), Category 2A (sor…	89

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Surgery	Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.	Limb-salvage surgery and endoprosthetic reconstruction		40

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.